Doctor Salah Mansour

Dr Salah Mansour

 PhD
Associate Professor

Research interests

  • Unconventional T cells and lipid antigen recognition in human disease
  • CD1-restricted T cell immunity, including group 1 CD1, iNKT and γδ T cells
  • Molecular and structural mechanisms of CD1-mediated antigen presentation

More research

Accepting applications from PhD students.

Connect with Salah

About

Dr Salah Mansour is an Associate Professor in Medicine at the University of Southampton, where he leads a multidisciplinary research programme focused on CD1-mediated immunity and unconventional T cells, including invariant natural killer T (iNKT) cells and γδ T cells. His work seeks to redefine how lipid antigens are recognised by the immune system and to exploit these pathways for therapeutic benefit in cancer, infectious diseases, and autoimmunity.

His laboratory integrates immunology, structural biology, and lipidomics to uncover fundamental mechanisms of antigen presentation and T cell activation, while driving their translation into novel immunotherapies. A major focus is the development of next-generation cancer immunotherapies that harness CD1-restricted and innate-like T cell populations, with emerging programmes in cell therapy and precision immune modulation.

Dr Mansour’s research is supported by major national and translational funders, including the Medical Research Council (MRC), Cancer Research UK (CRUK), Blood Cancer UK, and translational investment from LifeArc and CRUK Horizons (C-Further), alongside support from HEFCE and the Institute for Life Sciences. He has established a strong network of interdisciplinary and translational collaborations spanning synthetic chemistry, structural biology, and clinical research, and works closely with partners at UKHSA Porton Down, King’s College London, the Francis Crick Institute, and the Africa Health Research Institute in Durban.

Through these activities, he is building an integrated programme that spans discovery science through to translational development, aligning with the University of Southampton’s Institute for Medical Innovation (IMI) strategy to accelerate the development of next-generation immunotherapies.